Compare · CVRX vs RMD
CVRX vs RMD
Side-by-side comparison of CVRx Inc. (CVRX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.04B, about 187.7x CVRX ($144.1M).
- Over the past year, CVRX is down 16.1% and RMD is down 23.6% - CVRX leads by 7.5 points.
- CVRX has been more active in the news (7 items in the past 4 weeks vs 5 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- ResMed Inc.
- Price
- $5.43-2.42%
- $186.48-2.17%
- Market cap
- $144.1M
- $27.04B
- 1M return
- -27.14%
- -12.66%
- 1Y return
- -16.06%
- -23.58%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 5
- Recent ratings
- 13
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest CVRX
- SEC Form SD filed by CVRx Inc.
- CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- CVRx to Present at the William Blair 46th Annual Growth Stock Conference
- CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
- SEC Form 10-Q filed by CVRx Inc.
- CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CVRx Reports First Quarter 2026 Financial and Operating Results
- CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
- CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
Latest RMD
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
- Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition